-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Neutral on Quest Diagnostics, Raises Price Target to $200

Benzinga·04/28/2025 16:50:39
Listen to the news
Piper Sandler analyst David Westenberg maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $180 to $200.